Is the cohort recruitable, or just scientifically attractive?
Review biomarker burden, prior therapy, diagnosis path, screen-failure pressure, and competing studies.
Patient & site feasibility
Patient feasibility. Site selection. A clearer trial plan.
Patient feasibility, clinical trial site selection and PI prioritization for biotech teams. Supporting enrollment decisions in China NMPA and US/global trial planning.
The work
We pressure-test the assumptions that become expensive to change.
The output is not a generic platform demo. It is sponsor-side judgment: what to diligence first, what to challenge, and what not to lock too early.
Are first-wave sites chosen for execution fit or reputation?
Separate useful prestige from activation behavior, early-phase capability, mechanism experience, and patient access.
Which investigators look strong but may already be overloaded?
Flag recent trial load, similar-mechanism overlap, team capacity signals, and alternate investigator options.
Which feasibility assumptions deserve a direct challenge?
Turn timeline, screen-failure, testing, startup, and enrollment assumptions into CRO-facing questions.
Services
Start with the smallest review that answers the current decision.
If the decision is narrow, keep the work narrow. If the sponsor is already in CRO discussions, move into a deeper FIH Scout Plus review.
01FIH Readiness SnapshotScope: $10,000-$15,000 · Typical timing: 7-10 business daysBest fitDefined oncology asset, target, mechanism, modality, and preliminary indication.Sponsor receives15-25 page diagnostic memo, readiness conclusion, risk flags, and one readout call.02FIH Scout PlusScope: $45,000-$72,000 · Typical timing: 3-4 weeksBest fitDraft protocol synopsis or early development plan with uncertainty around U.S. execution assumptions.Sponsor receives50-80 page strategy report, 10-page executive deck, CRO briefing questions, and sponsor decision memo.03CRO Acceleration IntelligenceScope: $35,000-$85,000 + data cost if used · Typical timing: 2-4 weeksBest fitCRO already engaged, first-wave site list or startup plan available, and sponsor needs sharper prioritization before execution drifts.Sponsor receivesCRO acceleration memo, site priority challenge list, patient distribution review, CRO meeting questions, and next-action tracker.04RWD-Enabled Cohort & Site StrategyScope: $115,000-$190,000 + data cost · Typical timing: 6-8 weeksBest fitDefined U.S. FIH or Phase 1 plan with biomarker, line-of-therapy, or cohort availability uncertainty.Sponsor receives80-120 page strategy report, RWD feasibility framework, protocol risk redline, site archetype strategy, and sponsor readout.
Apex AI relationship
Research context, separated commercial delivery.
OncoLattice Bio / AAI Inc. handles commercial engagements. Apex AI is part of the broader research and technology context. That separation is deliberate: client work proceeds under appropriate licensing, governance, and written authorization.
Research foundation
Built with research foundations from the Apex AI ecosystem.
Commercial counterparty
Contracts, client work, and delivery run through OncoLattice Bio / AAI Inc.
Governance boundary
Apex AI references do not imply direct nonprofit service or automatic expert participation.
Bring your asset, indication, and target geography.
We help sponsors pressure-test the execution path before site lists, competitor assumptions, and global development commitments harden.